
Alvaro Urbano-Ispizua

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5998803/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. Frontiers in Oncology, 2022, 12, 828471.	2.8	19
2	Results of <scp>ARI</scp> â€0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp> â€positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	4.1	6
3	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplantation and Cellular Therapy, 2022, 28, 489.e1-489.e9.	1.2	7
4	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. Molecular Therapy, 2021, 29, 636-644.	8.2	80
5	IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers, 2021, 13, 3534.	3.7	19
6	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. Transplantation and Cellular Therapy, 2021, 27, 619.e1-619.e8.	1.2	15
7	CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?. Cancers, 2021, 13, 4664.	3.7	10
8	Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Leukemia, 2021, 35, 3585-3588.	7.2	72
9	Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 2760-2760.	1.4	Ο
10	Design and <i>in Vitro</i> Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Blood, 2021, 138, 4799-4799.	1.4	0
11	Poor Outcome of Patients with COVID-19 after CAR T-Cell Therapy for B-Cell Malignancies: Results from a Multicenter Study on Behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. Blood, 2021, 138, 2818-2818.	1.4	0
12	Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood, 2021, 138, 3925-3925.	1.4	0
13	Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells. Blood, 2021, 138, 480-480.	1.4	1
14	CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome. Blood, 2021, 138, 735-735.	1.4	7
15	First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. , 2021, 9, e003783.		17
16	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica, 2020, 105, 297-316.	3.5	230
17	Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. Haematologica, 2020, 106, 173-184.	3.5	25
18	Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1565-1574.	1.3	8

#	Article	IF	CITATIONS
19	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482.	4.8	77
20	Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. Bone Marrow Transplantation, 2020, 55, 1264-1271.	2.4	21
21	A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. Bone Marrow Transplantation, 2020, 55, 965-973.	2.4	15
22	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
23	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS ONE, 2020, 15, e0241778.	2.5	5
24	Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
25	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplantation, 2019, 54, 1295-1303.	2.4	6
26	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
27	Chimeric Antigen Receptor T Cells Targeting CD19 and Ibrutinib for Chronic Lymphocytic Leukemia. HemaSphere, 2019, 3, e174.	2.7	5
28	Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144.	4.1	77
29	Células CAR T: el futuro ya es presente. Medicina ClÃnica, 2019, 152, 281-286.	0.6	1
30	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer, 2018, 124, 2541-2551.	4.1	61
31	Single Antigen–Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1196-1202.	2.0	50
32	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1541-1547.	2.4	20
33	CAR-T cell therapy, a door is open to find innumerable possibilities of treatments for cancer patients. Turkish Journal of Haematology, 2018, 35, 217-228.	0.5	9
34	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Advances, 2018, 2, 1022-1031.	5.2	13
35	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Advances, 2018, 2, 299-307.	5.2	69
36	Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. Haematologica, 2017, 102, e76-e79.	3.5	15

#	Article	IF	CITATIONS
37	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2017, 105, 497-505.	1.6	4
38	Natural Killer Cells: Angels and Devils for Immunotherapy. International Journal of Molecular Sciences, 2017, 18, 1868.	4.1	59
39	Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity. Blood, 2016, 128, 2115-2115.	1.4	1
40	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 5421.	3.3	7
41	The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS ONE, 2015, 10, e0140454.	2.5	11
42	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1776-1782.	2.0	13
43	Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 236-244.	0.4	31
44	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2015, 21, 1746-1753.	2.0	48
45	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. Biology of Blood and Marrow Transplantation, 2015, 21, 640-645.	2.0	23
46	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
47	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clinical Cancer Research, 2015, 21, 2020-2028.	7.0	98
48	Cell-Cell Communication Between Multiple Myeloma (MM) Cells and Cord Blood Derived NK Cells (CB-NK) Regulates Both Tumor Cell Death and Tumor Cell Survival. Blood, 2015, 126, 1787-1787.	1.4	1
49	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. Blood, 2015, 126, 3209-3209.	1.4	1
50	Clinical Benefit of Eculizumab in Patients with No Transfusion History in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Blood, 2015, 126, 3340-3340.	1.4	0
51	Comparison of Tacrolimus Versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: A CIBMTR Analysis. Blood, 2014, 124, 4383-4383.	1.4	0
52	Trends In Incidence, Presentation, and Outcomes Of Chronic Graft-Versus-Host Disease In Allogeneic Transplantation- Report From The Center For International Blood and Marrow Transplant Research. Blood, 2013, 122, 3309-3309.	1.4	1
53	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis. Blood, 2013, 122, 2093-2093.	1.4	10
54	Risk assessment in haematopoietic stem cell transplantation: Stem cell source. Best Practice and Research in Clinical Haematology, 2007, 20, 265-280.	1.7	20

#	Article	IF	CITATIONS
55	Severe Donor Events after Allogeneic Hematopoietic Stem Cell Donation Blood, 2007, 110, 3276-3276.	1.4	1
56	Genetic Polymorphisms in the Inflammasomes Are Associated with Relapse and Survival in HLA-Identical Sibling Donor Allogeneic Stem Cell Transplantation Blood, 2007, 110, 1075-1075.	1.4	5
57	Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2006, 24, 4855-4861.	1.6	63
58	Effect of Germline Polymorphisms on Clinical Outcome in Hodgkin's Lymphoma (HL) Blood, 2006, 108, 2267-2267.	1.4	0
59	Costs of Imatinib, Costs of Transplants and Gross National Income Per Capita Impact on Transplant Rates for Chronic Myeloid Leukemia in European Countries Blood, 2006, 108, 2979-2979.	1.4	6
60	Analysis of microRNA Patterns in Hodgkin's Lymphoma (HL) Blood, 2006, 108, 474-474.	1.4	0
61	Impact of Dendritic Cell CD16+ Recovery on Outcome after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation Blood, 2005, 106, 1409-1409.	1.4	0
62	Polymorphisms of NOD2/CARD15 Are Associated with Clinical Outcome in T-Cell Depleted HLA-Identical Sibling Allogeneic Stem Cell Transplantation Blood, 2005, 106, 1408-1408.	1.4	0
63	Donor's Mannan-Binding Lectin (MBL) Gene Polymorphism Is Associated with Invasive Fungal Infection Following Allogeneic Stem Cell Transplantation Blood, 2004, 104, 2220-2220.	1.4	2
64	Retrospective Comparison of Using or Not Using Donor Lymphocyte Transfusion in the Treatment of Hematological Relapse after Allogeneic Stem Cell Transplantation in 489 Adults with Acute Myeloid Leukemia Blood, 2004, 104, 298-298.	1.4	1
65	Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood, 2002, 100, 724-727.	1.4	68
66	Immune Reconstitution Following Allogeneic Peripheral Blood Progenitor Cell Transplantation. Leukemia and Lymphoma, 2000, 37, 535-542.	1.3	12
67	Successful autografting in chronic myelogenous leukaemia using Philadelphia negative blood progenitor cells mobilized with rHuG-CSF alone in a patient responding to alpha-interferon. British Journal of Haematology, 1997, 96, 421-423.	2.5	8
68	Prognosis of Chronic Myeloid Leukemia: Studies from the Barcelona Group. Leukemia and Lymphoma, 1993, 11, 63-66.	1.3	35
69	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. British Journal of Haematology, 1992, 81, 178-183.	2.5	33
70	Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: Response to treatment and factors influencing outcome. Hematological Oncology, 1992, 10, 301-309.	1.7	7
71	Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. British Journal of Haematology, 1990, 75, 202-207.	2.5	66
72	A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. British Journal of Haematology, 1990, 76, 27-32.	2.5	49

#	Article	IF	CITATIONS
73	Adult T-cell Leukemia in a Chilean Resident in Spain: Long-Lasting Remission after 2-Deoxycoformycin Treatment. Leukemia and Lymphoma, 1989, 1, 47-49.	1.3	9